Healthcare stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.1%.
Immix Biopharma (IMMX) shares were nearly 8% higher after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.